00:49 , Sep 9, 2017 |  BioCentury  |  Strategy

Some of the parts

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. could put the industry-leading CAR T pipeline in the hands of the company best-suited to expand the cell therapies into the as-yet-elusive solid tumor space....
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Admune Therapeutics, Novartis deal

Novartis will acquire Admune for an undisclosed sum. Admune’s hetIL-15 is in Phase I testing to treat metastatic cancers. The product is a complex of IL-15 with a cleaved soluble form of the IL-15 receptor...
01:00 , Oct 22, 2015 |  BC Extra  |  Company News

Novartis strikes cancer deals with Admune, Palobiofarma

Novartis AG (NYSE:NVS; SIX:NOVN) bolstered its immuno-oncology pipeline with a pair of deals. The pharma acquired Admune Therapeutics LLC (Danvers, Mass.) and obtained exclusive, worldwide rights to non-small cell lung cancer (NSCLC) candidate PBF-509 from...
07:00 , May 4, 2015 |  BioCentury  |  Emerging Company Profile

Adding to immune function

Admune Therapeutics LLC is developing a heterodimeric complex of IL-15 to boost the immune system's response to cancer immunotherapies by increasing the number of antitumor lymphocytes overall and in the vicinity of tumors. Tumors' responses...